Qube Research & Technologies (QRT)
HOWL icon

Qube Research & Technologies (QRT)’s Werewolf Therapeutics HOWL Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-29,250
Closed -$57.6K – 3839
2025
Q3 		$57.6K Sell
29,250
-15,011
-34% -$20.6K ﹤0.01% 3162
2025
Q2 		$48.2K Buy
+44,261
New +$45.6K ﹤0.01% 3156
2024
Q3 		– Sell
-8,315
Closed -$20.3K – 3657
2024
Q2 		$20.3K Sell
8,315
-108,698
-93% -$522K ﹤0.01% 2880
2024
Q1 		$758K Buy
117,013
+114,629
+4,808% +$668K ﹤0.01% 2308
2023
Q4 		$9.2K Buy
2,384
+2,382
+119,100% +$6.08K ﹤0.01% 3617
2023
Q3 		$4 Buy
+2
New +$6 ﹤0.01% 3974
2022
Q4 		– Sell
-19,908
Closed -$90K – 2694
2022
Q3 		$90K Sell
19,908
-2,627
-12% -$14.3K ﹤0.01% 2001
2022
Q2 		$92K Buy
+22,535
New +$103K ﹤0.01% 1968

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Qube Research & Technologies (QRT)'s HOWL Position: Q4 2025 in Review

Qube Research & Technologies (QRT) sold out of Werewolf Therapeutics (HOWL) in Q4 2025, closing a stake of 29,250 shares — an estimated $57.6K sold.

Qube Research & Technologies (QRT) first reported a position in HOWL in Q2 2022 and held it in 8 quarters. The position peaked at $758K in Q1 2024. 51 funds tracked by Wall St. Rank hold HOWL as of Q4 2025.

  • Qube Research & Technologies (QRT) reported no remaining Werewolf Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 29,250 Werewolf Therapeutics shares in Q4 2025, an estimated $57.6K.
  • Qube Research & Technologies (QRT) first reported a position in Werewolf Therapeutics in Q2 2022 and held it in 8 quarters.
  • Qube Research & Technologies (QRT)'s Werewolf Therapeutics position peaked at $758K in Q1 2024.
  • 51 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q4 2025.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q4 2025, filed 17 Feb 2026.